Things may not have played out to plan for Biocon’s partnered biosimilar rival to NovoLog (insulin aspart), but the Indian firm is hopeful that a US approval should be in place towards the end of 2022.
While a response to the US Food and Drug Administration complete response letter for the Viatris-partnered biosimilar has been...






